Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog
- PMID: 6475789
- DOI: 10.1016/0002-9149(84)90267-4
Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog
Abstract
Encainide is highly effective in suppressing most nonsustained ventricular arrhythmias, but there is evidence that the drug is less effective and may worsen some arrhythmias, particularly in patients with sustained ventricular tachycardia. In most patients it is likely that the major antiarrhythmic effects of encainide are mediated through a potent metabolite, O-demethyl encainide. The effects of infusions of saline solution or O-demethyl encainide on spontaneous ventricular ectopic activity and ventricular fibrillation (VF) threshold were compared in 25 dogs with a mottled myocardial infarct produced by transient coronary occlusion. Plasma levels of the metabolite above 100 ng/ml suppressed (greater than 92%) the spontaneous ventricular ectopic activity that occurred 48 hours after MI, whereas saline solution had no effect. In 15 dogs treated with O-demethyl encainide, the VF threshold decreased an average of 23%, from a baseline level of 23 +/- 8 mA to 18 +/- 9 mA (p less than 0.05). There was a concentration-dependent fall in VF threshold with plasma concentrations of O-demethyl encainide above 150 ng/ml. In 2 dogs with very high plasma concentrations of the metabolite (greater than 1,000 ng/ml), VF was induced by right ventricular pacing alone (S1S1 300 ms). No change in VF threshold was observed in the 8 dogs treated with saline solution, and in each of these dogs VF could be terminated by the countershock protocol. However, in 7 of the 17 dogs treated with O-demethyl encainide, VF could not be terminated by the countershock protocol.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Electrophysiology of O-demethyl encainide in a canine model of sustained ventricular tachycardia.J Cardiovasc Pharmacol. 1984 Jul-Aug;6(4):588-95. doi: 10.1097/00005344-198407000-00006. J Cardiovasc Pharmacol. 1984. PMID: 6206311
-
Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.Circulation. 1989 Nov;80(5):1247-58. doi: 10.1161/01.cir.80.5.1247. Circulation. 1989. PMID: 2805262
-
Electrophysiologic actions of O-demethyl encainide: an active metabolite.Circulation. 1983 Aug;68(2):385-91. doi: 10.1161/01.cir.68.2.385. Circulation. 1983. PMID: 6861313
-
Encainide: a new antiarrhythmic agent.Drug Intell Clin Pharm. 1986 Jan;20(1):9-13. doi: 10.1177/106002808602000101. Drug Intell Clin Pharm. 1986. PMID: 3080301 Review.
-
Electrophysiology, hemodynamic and arrhythmia efficacy model studies on encainide.Am J Cardiol. 1986 Aug 29;58(5):10C-17C. doi: 10.1016/0002-9149(86)90098-6. Am J Cardiol. 1986. PMID: 3092614 Review.
Cited by
-
Encainide. A review of its pharmacological properties and therapeutic efficacy.Drugs. 1987 Nov;34(5):519-38. doi: 10.2165/00003495-198734050-00002. Drugs. 1987. PMID: 3121275 Review.
-
Evaluation of the efficacy and tolerance of the antiarrhythmic agent transcainide (R 54718).Eur J Clin Pharmacol. 1987;32(5):449-56. doi: 10.1007/BF00637668. Eur J Clin Pharmacol. 1987. PMID: 2441995
-
Clinical pharmacokinetics of encainide.Clin Pharmacokinet. 1988 Mar;14(3):141-7. doi: 10.2165/00003088-198814030-00002. Clin Pharmacokinet. 1988. PMID: 3131058 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources